SLC2A1 and neoplasm: Given the differential accumulation of glyCAF in the immune-excluded tumors, we next tested if GLUT1 inhibition (GLUT1i, BAY-876) is sufficient to reprogram the glyCAF metabolism and promote the infiltration of CD8+ T cells in the inner tumor parenchyma.